Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 4OTHER_GOV 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Breast Neoplasms 349Neoplasm Metastasis 31Stomach Neoplasms 30HER2-positive Breast Cancer 19Neoplasms 16Breast Neoplasms, Male 16Brain Neoplasms 13Inflammatory Breast Neoplasms 12Esophageal Neoplasms 10Colorectal Neoplasms 10Triple Negative Breast Neoplasms 8Adenocarcinoma 7Prostatic Neoplasms 6Cardiotoxicity 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Lung Neoplasms 5Carcinoma, Ductal, Breast 5Biliary Tract Neoplasms 5Salivary Gland Neoplasms 4Pathologic Complete Response 4Pancreatic Neoplasms 4Meningeal Neoplasms 4Colonic Neoplasms 4Breast Diseases 4Recurrence 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Gallbladder Neoplasms 3Carcinoma, Lobular 3

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Trastuzumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 2 Completed
43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
65 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡